A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Trial status:Recruiting
Trial ID:
GO44479
NCT ID:
NCT05968326
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Recruiting

Trial Details

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Medical Condition
  • Pancreatic Cancer
    • Trial Drug
  • Autogene cevumeran
    • See more
  • Atezolizumab
  • mFOLFIRINOX
    • Phase
    Phase 2
    Type
    Interventional
    Estimated Enrolment
    260
    Estimated Trial Date
    Oct 2023 - Dec 2029

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    USC Norris Comprehensive Cancer Center
    Los Angeles, California, United States, 90033
    Status
    Recruiting
    Location
    University of California Los Angeles
    Los Angeles, California, United States, 90095
    Status
    Recruiting
    Location
    USC Norris Cancer Center
    Newport Beach, California, United States, 92663
    Status
    Recruiting
    Location
    University of California, San Francisco (UCSF)
    San Francisco, California, United States, 94158
    Status
    Recruiting
    Location
    St. Francis Hospital and Medical Center
    Hartford, Connecticut, United States, 06105
    Status
    Recruiting
    Location
    Smilow Cancer Center
    New Haven, Connecticut, United States, 06510
    Status
    Withdrawn